Stockscreener 앱 받기
4.40
3.53%
0.15
시간 외 거래:
4.40
Macrogenics Inc 주식(MGNX)의 최신 뉴스
Macrogenics Inc (MGNX) Senior VP, GC, and Secretary Jeffrey Pete - GuruFocus
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com Australia
Macrogenics senior VP sells $129,085 in shares - Investing.com
MacroGenics (MGNX) counsel sells 31K shares, now holds none - Stock Titan
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
MacroGenics (NASDAQ: MGNX) officer prepares stock sales under Rule 144 - Stock Titan
MacroGenics (MGNX) Q1 2026 Results: The Bottom-Line Figure Beats Its Comparison in the Latest Session - vinanet.vn
MacroGenics (MGNX) exec adds 40K shares via option exercise - Stock Titan
MacroGenics (NASDAQ: MGNX) insider lines up new stock sale after recent trade - Stock Titan
MGNX Maintained by B. Riley Securities -- Price Target Raised to $11.00 - GuruFocus
B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating - marketscreener.com
MacroGenics (MGNX) Stock Faces A Revenue Reality Check After Deeper Losses - Sahm
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance
MacroGenics 2026: Revenue $32.83M, EPS $0.31— 10-Q Summary - TradingView
MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise - Stock Titan
Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A - Stock Titan
MacroGenics Inc earnings missed by $1.02, revenue fell short of estimates - Investing.com Nigeria
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position - The Manila Times
MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS - MarketBeat
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
MacroGenics sells GMP ops to Bora for $122.5 million - scanx.trade
MacroGenics Q2 adj. EPS $(0.27) misses $(0.13) estimate; sales miss - scanx.trade
MacroGenics: Q2 Earnings Snapshot - AOL.com
MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner - marketscreener.com
Gilead exercises option for MacroGenics pre-clinical bispecific program - The Pharma Letter
MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP - MarketBeat
MacroGenics、2026年第2四半期の財務結果を発表、運営モデルのスリム化と財務基盤の強化を実現 - Moomoo
MGNX Q1 2026 Earnings: Narrow EPS Surprise Slightly Offsets Stock DeclineEarnings Surprise Report - Vinanet
Gilead exercises option on MacroGenics bispecific program By Investing.com - Investing.com UK
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - The Manila Times
MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com Nigeria
MacroGenics stock rises on $10M Gilead option exercise - Investing.com
Gilead exercises option on MacroGenics bispecific program - Investing.com
MacroGenics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
MacroGenics (MGNX) Projected to Release Earnings on Thursday - MarketBeat
MGNX (NASDAQ: MGNX) holder files to sell 20,166 common shares under Rule 144 - stocktitan.net
Bank of America (NYSE: BAC) reports 4.0% beneficial stake in MacroGenics (MGNX) - Stock Titan
MacroGenics Inc (MGNX) Institutional Confidence - TradingKey
BlackRock (MGNX holder) discloses 7.1% MacroGenics stake in Schedule 13G filing - Stock Titan
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important (MGNX) - Seeking Alpha
Citizens reiterates MacroGenics stock rating ahead of ESMO data - Investing.com
Citizens reiterates MacroGenics stock rating ahead of ESMO data By Investing.com - Investing.com Canada
MacroGenics Inc (MGNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MacroGenics, Inc. Revenue Breakdown – NASDAQ:MGNX - tradingview.com
MacroGenics Inc (MGNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
MGNX|MacroGenics Inc|Price:3.700|Chg%:-0.310 - TradingKey
MacroGenics Inc (MGNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MacroGenics Inc (MGNX) Cash Flow - TradingKey
MacroGenics, Inc. Revenue Breakdown – DUS:M55 - TradingView
TradingKey - TradingKey
MacroGenics slips on trial data for lead asset (MGNX:NASDAQ) - Seeking Alpha
MacroGenics’ MGC026 meets Phase 1 trial milestone in SCCHN - Investing.com
MacroGenics (MGNX) Advances Phase 1 Study of MGC026 - GuruFocus
0.86%
0.31%
자본화:
|
볼륨(24시간):